Literature DB >> 29345365

Deletion of BCG Hip1 protease enhances dendritic cell and CD4 T cell responses.

Erica Bizzell1, Jonathan Kevin Sia1, Melanie Quezada1, Ana Enriquez1, Maria Georgieva1,2, Jyothi Rengarajan1,3.   

Abstract

Dendritic cells (DCs) play a key role in the generation of CD4 T cell responses to pathogens. Mycobacterium tuberculosis (Mtb) harbors immune evasion mechanisms that impair DC responses and prevent optimal CD4 T cell immunity. The vaccine strain Mycobacterium bovis Bacille Calmette-Guérin (BCG) shares many of the immune evasion proteins utilized by Mtb, but the role of these proteins in DC and T cell responses elicited by BCG is poorly understood. We previously reported that the Mtb serine protease, Hip1, promotes sub-optimal DC responses during infection. Here, we tested the hypothesis that BCG Hip1 modulates DC functions and prevents optimal antigen-specific CD4 T cell responses that limit the immunogenicity of BCG. We generated a strain of BCG lacking hip1 (BCGΔhip1) and show that it has superior capacity to induce DC maturation and cytokine production compared with the parental BCG. Furthermore, BCGΔhip1-infected DCs were more effective at driving the production of IFN-γ and IL-17 from antigen-specific CD4 T cells in vitro. Mucosal transfer of BCGΔhip1-infected DCs into mouse lungs induced robust CD4 T cell activation in vivo and generated antigen-specific polyfunctional CD4 T cell responses in the lungs. Importantly, BCGΔhip1-infected DCs enhanced control of pulmonary bacterial burden following Mtb aerosol challenge compared with the transfer of BCG-infected DCs. These results reveal that BCG employs Hip1 to impair DC activation, leading to attenuated lung CD4 T cell responses with limited capacity to control Mtb burden after challenge. ©2017 Society for Leukocyte Biology.

Entities:  

Keywords:  immune evasion; immunogenicity; tuberculosis; vaccine

Mesh:

Substances:

Year:  2017        PMID: 29345365      PMCID: PMC6457460          DOI: 10.1002/JLB.4A0917-363RR

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  7 in total

Review 1.  Immunology of Mycobacterium tuberculosis Infections.

Authors:  Jonathan Kevin Sia; Jyothi Rengarajan
Journal:  Microbiol Spectr       Date:  2019-07

2.  Mycobacterium tuberculosis impedes CD40-dependent notch signaling to restrict Th17 polarization during infection.

Authors:  Ana Beatriz Enriquez; Jonathan Kevin Sia; Hedwin Kitdorlang Dkhar; Shu Ling Goh; Melanie Quezada; Kristina Larrieux Stallings; Jyothi Rengarajan
Journal:  iScience       Date:  2022-04-26

Review 3.  BCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design.

Authors:  Camila Covián; Ayleen Fernández-Fierro; Angello Retamal-Díaz; Fabián E Díaz; Abel E Vasquez; Margarita K Lay; Claudia A Riedel; Pablo A González; Susan M Bueno; Alexis M Kalergis
Journal:  Front Immunol       Date:  2019-11-29       Impact factor: 7.561

Review 4.  The double-sided effects of Mycobacterium Bovis bacillus Calmette-Guérin vaccine.

Authors:  Junli Li; Lingjun Zhan; Chuan Qin
Journal:  NPJ Vaccines       Date:  2021-01-25       Impact factor: 7.344

Review 5.  Advancing Adjuvants for Mycobacterium tuberculosis Therapeutics.

Authors:  Ana B Enriquez; Angelo Izzo; Shannon M Miller; Erica L Stewart; Robert N Mahon; Daniel J Frank; Jay T Evans; Jyothi Rengarajan; James A Triccas
Journal:  Front Immunol       Date:  2021-10-25       Impact factor: 8.786

6.  Elevated IL-35 level and iTr35 subset increase the bacterial burden and lung lesions in Mycobacterium tuberculosis-infected mice.

Authors:  Fangliu Yu; Xinying Zhu; Qingdeng Li; Wenqin Xu; Yunxing Gao; Yufeng Wen; Qiong Zhang; Jun Dou
Journal:  Open Life Sci       Date:  2022-03-31       Impact factor: 0.938

Review 7.  BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic?

Authors:  A R Sharma; G Batra; M Kumar; A Mishra; R Singla; A Singh; R S Singh; B Medhi
Journal:  Allergol Immunopathol (Madr)       Date:  2020-07-03       Impact factor: 1.667

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.